KINE 701
Alternative Names: KINE-701Latest Information Update: 14 Oct 2024
At a glance
- Originator Kine Sciences
- Class Anti-ischaemics; Cardiovascular therapies; Peptides
- Mechanism of Action Angiogenesis modulating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 14 Oct 2024 Discontinued - Preclinical for Myocardial infarction in South Korea (unspecified route) (Kine Sciences pipeline, October 2024)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Myocardial-infarction in South Korea
- 12 May 2020 Preclinical trials in Myocardial infarction in South Korea (unspecified route), prior to May 2020 (Kine Sciences pipeline, May 2020)